News > Lupin launches Covihalt for treatment of mild Covid-19

Lupin launches Covihalt for treatment of mild Covid-19

Pharma major Lupin Limited today announced the launch of its Favipiravir in India under the brand name Covihalt for the treatment of mild to moderate Covid-19. Favipiravir has received authorization from the DCGI for emergency use.

Lupin’s Covihalt dosage strength has been developed keeping in mind the convenience of administration. It is available as 200 mg tablets in the form of a strip of 10 tablets and priced at Rs 49 per tablet.